Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has been assigned an average rating of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $45.7143.

Several research firms recently commented on ZBIO. Morgan Stanley raised their target price on Zenas BioPharma from $22.00 to $32.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. HC Wainwright reiterated a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Citigroup reissued a “buy” rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Guggenheim reissued a “buy” rating and set a $55.00 price target on shares of Zenas BioPharma in a report on Friday, August 14th. Finally, Weiss Ratings cut shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th.

Institutional Trading of Zenas BioPharma

A number of institutional investors have recently made changes to their positions in the stock. Quarry LP increased its stake in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the period. Russell Investments Group Ltd. acquired a new stake in Zenas BioPharma in the third quarter worth approximately $30,000. Quantbot Technologies LP acquired a new stake in Zenas BioPharma in the second quarter worth approximately $49,000. CWM LLC boosted its stake in Zenas BioPharma by 48.3% during the 4th quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Zenas BioPharma during the 4th quarter valued at $95,000.

Zenas BioPharma Stock Down 1.3%

Zenas BioPharma stock opened at $32.62 on Friday. The company has a debt-to-equity ratio of 1.57, a quick ratio of 9.93 and a current ratio of 9.93. Zenas BioPharma has a one year low of $13.50 and a one year high of $44.60. The company has a 50-day simple moving average of $29.39 and a 200-day simple moving average of $24.16. The firm has a market capitalization of $2.13 billion, a P/E ratio of -3.63 and a beta of -1.03.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The company had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $15.00 million. As a group, equities analysts expect that Zenas BioPharma will post -5.81 earnings per share for the current year.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.